🇺🇸 Imipenem+Relebactam in United States

119 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pseudomonas Infection — 16 reports (13.45%)
  2. Sepsis — 15 reports (12.61%)
  3. Pathogen Resistance — 14 reports (11.76%)
  4. Renal Failure — 14 reports (11.76%)
  5. Drug Ineffective — 12 reports (10.08%)
  6. Nephropathy Toxic — 11 reports (9.24%)
  7. Febrile Neutropenia — 10 reports (8.4%)
  8. Thrombocytopenia — 10 reports (8.4%)
  9. Ototoxicity — 9 reports (7.56%)
  10. Cellulitis — 8 reports (6.72%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Imipenem+Relebactam approved in United States?

Imipenem+Relebactam does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Imipenem+Relebactam in United States?

Wake Forest University Health Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.